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Abstract
Background: The CONSORT (Consolidated Standards of Reporting Trials) Statement was developed to help
biomedical researchers report randomised controlled trials (RCTs) transparently. We have developed an extension to
the CONSORT 2010 Statement for social and psychological interventions (CONSORT-SPI 2018) to help behavioural
and social scientists report these studies transparently.
Methods: Following a systematic review of existing reporting guidelines, we conducted an online Delphi process
to prioritise the list of potential items for the CONSORT-SPI 2018 checklist identified from the systematic review. Of
384 international participants, 321 (84%) participated in both rating rounds. We then held a consensus meeting of
31 scientists, journal editors, and research funders (March 2014) to finalise the content of the CONSORT-SPI 2018
checklist and flow diagram.
Results: CONSORT-SPI 2018 extends 9 items (14 including sub-items) from the CONSORT 2010 checklist, adds a
new item (with 3 sub-items) related to stakeholder involvement in trials, and modifies the CONSORT 2010 flow
diagram. This Explanation and Elaboration (E&E) document is a user manual to enhance understanding of
CONSORT-SPI 2018. It discusses the meaning and rationale for each checklist item and provides examples of
complete and transparent reporting.
Conclusions: The CONSORT-SPI 2018 Extension, this E&E document, and the CONSORT website (www.consort-
statement.org) are helpful resources for improving the reporting of social and psychological intervention RCTs.
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Background
CONSORT-SPI 2018 explanation and elaboration
The CONSORT (Consolidated Standards of Reporting
Trials) Statement was developed to help authors report
randomised controlled trials (RCTs) [1]. It has improved
the quality of reports in medicine [2–5], and has been
officially endorsed by over 600 journals and prominent
editorial groups [6]. A smaller number of journals have
implemented CONSORT—particularly its extension state-
ments—as a requirement for the manuscript submission,
peer-review, and editorial decision-making process [6, 7].
There are extensions of the CONSORT Statement (http://
www.consort-statement.org/extensions) for specific trial
designs [8–11], types of data (e.g. patient-reported
outcomes, harms, and information in abstracts) [12–14],
and interventions [15–17].
Several reviews have shown that RCTs of social and
psychological interventions are often not reported with
sufficient accuracy, comprehensiveness, and transparency
to replicate these studies, assess their quality, and under-
stand for whom and under what circumstances the evalu-
ated intervention should be delivered [18–22]. Moreover,
behavioural and social scientists may be prevented from re-
producing or synthesising previous studies because trial
protocols, outcome data, and the materials required to im-
plement social and psychological interventions are often
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not shared [23–28]. These inefficiencies contribute to sub-
optimal dissemination of effective interventions [29, 30],
overestimation of intervention efficacy [31], and research
waste [29]. Transparent and detailed reporting of social and
psychological intervention RCTs is needed to minimise
reporting biases and to maximise the credibility and utility
of this research evidence [32, 33].
We developed an extension of the CONSORT 2010
Statement for Social and Psychological Interventions
(CONSORT-SPI 2018) [34]. To delineate the scope of
CONSORT-SPI 2018, we defined interventions by their
mechanisms of action [35, 36]. We define social and psy-
chological interventions as actions intended to modify
processes and systems that are social and psychological
in nature (such as cognitions, emotions, behaviours,
norms, relationships, and environments) and are
hypothesised to influence outcomes of interest [37, 38].
Social and psychological interventions may be offered to
individuals who request them or as a result of policy,
may operate at different levels (e.g., individual, group,
place), and are usually “complex” [19]. CONSORT-SPI
2018 is designed primarily for reports of RCTs, though
some parts of this guidance may be useful for re-
searchers conducting other types of clinical trials [39] or
who are interested in developing and evaluating complex
interventions [40]. In addition, although terms in this re-
port are most appropriate for parallel-group trials, the
guidance is designed to apply to other designs (e.g.
stepped wedge and N of 1).
Methods
We previously reported the methods used to develop
CONSORT-SPI 2018 [41]. In summary, we first con-
ducted systematic reviews of existing guidance and qual-
ity of trial reporting [18]. Second, we conducted an
international online Delphi process between September
2013 and February 2014 to prioritise the list of potential
items for the CONSORT-SPI 2018 checklist and flow
diagram that were identified in the systematic review.
Survey items can be accessed at the project’s ReShare
site: 10.5255/UKDA-SN-851981. Third, we held a con-
sensus meeting to finalise the content of the checklist
and flow diagram. The meeting was held in March 2014
and comprised 31 scientists, journal editors, and re-
search funders. A writing group drafted CONSORT-SPI
2018, and consensus group participants provided feed-
back and agreed to the final manuscript for the
CONSORT-SPI 2018 Extension Statement [42], and this
Explanation and Elaboration (E&E) document
(Additional file 1: Table S1).
The CONSORT-SPI 2018 checklist extends 9 of the 25
items (incorporating 14 sub-items) found in CONSORT
2010 (Table 1; new items are in the ‘CONSORT-SPI 2018’
column) and includes a modified flow diagram. Participants
also voted to add a new item about stakeholder involve-
ment, and they recommended modifications to existing
CONSORT 2010 checklist items (Table 2). This E&E docu-
ment briefly summarises the content from the CONSORT
2010 E&E document for each CONSORT 2010 item [43],
tailored to a behavioural and social science audience, and it
provides an explanation and elaboration for the new items
in CONSORT-SPI 2018. Specifically, for each item from
CONSORT 2010 and CONSORT-SPI 2018, this E&E pro-
vides the rationale for the checklist item and examples of
reporting for a behavioural and social science audience
(Additional file 2: Table S2). Throughout this article, we use
the term ‘participants’ to mean ‘participating units’ targeted
by interventions, which might be individuals, groups, or
places (i.e. settings or locations) [44]. While we include a
brief statement about each item in the CONSORT 2010
checklist, readers can find additional information about
these items on the CONSORT website (www.consort-state-
ment.org) and the CONSORT 2010 E&E [43].
Results and Discussion
Explanation and elaboration of the CONSORT-SPI
Title and abstract
Item 1a: identification as a randomised trial in the
title Placing the word ‘randomised’ in the title increases
the likelihood that an article will be indexed correctly in
bibliographic databases and retrieved in electronic
searches [45]. Authors should consider providing infor-
mation in the title to assist interested readers, such as
the name of the intervention and the problem that the
trial addresses [46]. We advise authors to avoid unin-
formative titles (e.g. catchy phrases or allusions) because
they reduce space that could be used to help readers
identify relevant manuscripts [45, 46].
Item 1b: structured summary of trial design, methods,
results, and conclusions (for specific guidance, see
CONSORT for Abstracts) [13, 47] Abstracts are the
most widely read section of manuscripts [46], and they are
used for indexing reports in electronic databases [45].
Authors should follow the CONSORT Extension for
Abstracts, which provides detailed advice for structured
journal article abstracts and for conference abstracts.
We have tailored the CONSORT Extension for Abstracts
for social and psychological intervention trials with rele-
vant items for the objective, trial design, participants, and
interventions from the CONSORT-SPI 2018 checklist
(Table 3 and Additional file 3) [47].
Introduction
Item 2a: scientific background and explanation of
rationale A structured introduction should describe the
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rationale for the trial and how the trial contributes to
what is known [48]. In particular, the introduction
should describe the targeted problem or issue [49] and
what is already know about the intervention, ideally by
referencing systematic reviews [46].
Item 2b: specific objectives or hypotheses The objec-
tives summarise the research questions, including any hy-
potheses about the expected magnitude and direction of
intervention effects [48, 50]. For social and psychological
interventions that have multiple units of intervention and
multiple outcome assessments (e.g. individuals, groups,
places), authors should specify to whom or to what each
objective and hypothesis applies.
CONSORT-SPI 2018 item 2b: if pre-specified, how the
intervention was hypothesised to work
Describing how the interventions in all groups (i.e. all
experimental and comparator groups) were expected to
affect outcomes provides important information about
the theory underlying the interventions [46]. For each
intervention evaluated, authors should describe the
'mechanism of action' [51], also known as the 'theory of
change' [52], 'programme theory' [53], or 'causal path-
way' [54]. Authors should state how interventions were
thought to affect outcomes prior to the trial, and
whether the hypothesised mechanisms of action were
specified a priori, ideally with reference to the trial regis-
tration and protocol [55]. Specifically, authors should
report: how the components of each intervention were
expected to influence modifiable psychological and
social processes, how influencing these processes was
thought to affect the outcomes of interest, the role of
context, facilitators of and barriers to intervention
implementation, and potential adverse events or unin-
tended consequences [48, 56]. Graphical depictions—
such as a logic model or analytic framework—may be
useful [19].
Fig. 1 The CONSORT-SPI 2018 flow diagram
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Table 1 The CONSORT-SPI 2018 checklist
Section Item # CONSORT 2010 CONSORT-SPI 2018
Title and abstract 1a Identification as a randomised trial in the title§
1b Structured summary of trial design, methods, results, and
conclusions (for specific guidance, see CONSORT for
Abstracts)§
Refer to CONSORT extension for social and
psychological intervention trial abstracts
Introduction
Background and
objectives
2a Scientific background and explanation of rationale§
2b Specific objectives or hypotheses§ If pre-specified, how the intervention was
hypothesised to work
Methods
Trial design 3a Description of trial design (such as parallel, factorial)
including allocation ratio§
If the unit of random assignment is not the
individual, please refer to CONSORT for
Cluster Randomised Trials [8]
3b Important changes to methods after trial commencement
(such as eligibility criteria), with reasons
Participants 4a Eligibility criteria for participants§ When applicable, eligibility criteria for
settings and those delivering the
interventions
4b Settings and locations where the data were collected
Interventions 5 The interventions for each group with sufficient details to
allow replication, including how and when they were
actually administered§
5a Extent to which interventions were actually
delivered by providers and taken up by
participants as planned
5b Where other informational materials about
delivering the intervention can be accessed
5c When applicable, how intervention providers
were assigned to each group
Outcomes 6a Completely defined pre-specified outcomes, including how
and when they were assessed§
6b Any changes to trial outcomes after the trial commenced,
with reasons
Sample size 7a How sample size was determined§
7b When applicable, explanation of any interim analyses and
stopping guidelines
Randomisation
Sequence generation 8a Method used to generate the random allocation sequence
8b Type of randomisation and details of any restriction (such as
blocking and block size)§
Allocation concealment
mechanism
9 Mechanism used to implement the random allocation
sequence, describing any steps taken to conceal the
sequence until interventions were assigned§
Implementation 10 Who generated the random allocation sequence, who enrolled
participants, and who assigned participants to interventions§
Awareness of assignment 11a Who was aware of intervention assignment after allocation (for
example, participants, providers, those assessing outcomes),
and how any masking was done
11b If relevant, description of the similarity of interventions
Analytical methods 12a Statistical methods used to compare group outcomes§ How missing data were handled, with details
of any imputation method
12b Methods for additional analyses, such as subgroup analyses,
adjusted analyses, and process evaluations
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Methods: trial design
Item 3a: description of trial design (such as parallel,
factorial) including allocation ratio Unambiguous de-
tails about trial design help readers assess the suitability
of trial methods for addressing trial objectives [46, 57],
and clear and transparent reporting of all design features
of a trial facilitates reproducibility and replication [58].
Authors should explain their choice of design (especially
if it is not an individually randomised, two-group parallel
trial) [9]; state the allocation ratio and its rationale; and
indicate whether the trial was designed to assess the
superiority, equivalence, or noninferiority of the inter-
ventions [10, 59, 60].
Table 1 The CONSORT-SPI 2018 checklist (Continued)
Section Item # CONSORT 2010 CONSORT-SPI 2018
Results
Participant flow (a diagram
is strongly recommended)
13a For each group, the numbers randomly
assigned, receiving the intended intervention,
and analysed for the outcomes§
Where possible, the number approached,
screened, and eligible prior to random
assignment, with reasons for non-enrolment
13b For each group, losses and exclusions after randomisation,
together with reasons§
Recruitment 14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped
Baseline data 15 A table showing baseline characteristics for each group§ Include socioeconomic variables where
applicable
Numbers analysed 16 For each group, number included in each analysis
and whether the analysis was by original assigned groups§
Outcomes and estimation 17a For each outcome, results for each group, and the
estimated effect size and its precision (such as 95% confidence
interval)§
Indicate availability of trial data
17b For binary outcomes, presentation of both absolute and
relative effect sizes is recommended
Ancillary analyses 18 Results of any other analyses performed, including subgroup
analyses, adjusted analyses, and process evaluations,
distinguishing pre-specified from exploratory
Harms 19 All important harms or unintended effects in each group (for
specific guidance, see CONSORT for Harms)
Discussion
Limitations 20 Trial limitations, addressing sources of potential bias,
imprecision, and, if relevant, multiplicity of analyses
Generalisability 21 Generalisability (external validity, applicability) of the trial
findings§
Interpretation 22 Interpretation consistent with results, balancing benefits
and harms, and considering other relevant evidence
Important information
Registration 23 Registration number and name of trial registry
Protocol 24 Where the full trial protocol can be accessed, if available
Declaration of interests 25 Sources of funding and other support, role of funders Declaration of any other potential interests
Stakeholder involvement 26a Any involvement of the intervention
developer in the design, conduct, analysis, or
reporting of the trial
26b Other stakeholder involvement in trial design,
conduct, or analyses
26c Incentives offered as part of the trial
This table lists items from the CONSORT 2010 checklist (with some modifications for social and psychological intervention trials as described in Table 2) and
additional items in the CONSORT-SPI 2018 extension. Empty rows in the ‘CONSORT-SPI 2018’ column indicate that there is no extension to the CONSORT
2010 item
We strongly recommended that the CONSORT-SPI 2018 Explanation and Elaboration (E&E) document be reviewed when using the CONSORT-SPI 2018 checklist
for important clarifications of each item
§An extension item for cluster trials exists for this CONSORT 2010 item
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CONSORT-SPI 2018 item 3a: if the unit of random
assignment is not the individual, please refer to CONSORT
for Cluster Randomised Trials
Randomising at the cluster level (e.g. schools) has
important implications for trial design, analysis, infer-
ence, and reporting. For cluster randomised trials,
authors should follow the CONSORT Extension to
Cluster Randomised Trials. Because many social and
psychological interventions are cluster randomised, we
provide the extended items from this checklist in
Tables 4 and 5 [8]. Authors should also report the
unit of randomisation, which might be social units
(e.g. families), organisations (e.g. schools, prisons), or
places (e.g. neighbourhoods), and specify the unit of
each analysis, especially when the unit of analysis is
not the unit of randomisation (e.g. randomising at the
cluster level and analysing outcomes assessed at the
individual level).
Item 3b: important changes to methods after trial
commencement (such as eligibility criteria), with rea-
sons Deviations from planned trial methods are com-
mon, and not necessarily associated with flawed or
biased research. Changes from the planned methods are
important for understanding and interpreting trial re-
sults. A trial report should refer to a trial registration
(Item 23) [61–63] and protocol (Item 24) developed in
advance of assigning the first participant [55], and to a
pre-specified statistical analysis plan [64]. The report
should summarise all amendments to the protocol and
statistical analysis plan, when they were made, and the
rationale for each amendment. Because selective out-
come reporting is pervasive [65], authors should state
any changes to the outcome definitions during the trial.
Methods: participants
Item 4a: eligibility criteria for participants Eligibility
criteria should describe how participants (i.e. individuals,
groups, or places) were recruited. Readers need this
information to understand who could have entered
the trial and the generalisability of findings. Authors
should describe all inclusion and exclusion criteria
used to determine eligibility, as well as the methods
used to screen and assess participants to determine
their eligibility [46, 48].
CONSORT-SPI 2018 item 4a: when applicable, eligibility
criteria for settings and those delivering the interventions
In addition to the eligibility criteria that apply to individ-
uals, social and psychological intervention trials often
have eligibility criteria for the settings where participants
will be recruited and interventions delivered, as well as
intervention providers [44]. Authors should describe
these criteria to help readers compare the trial context
with other contexts in which interventions might be
used [48, 66, 67].
Item 4b: settings and locations of intervention deliv-
ery and where the data were collected Information
about settings and locations of intervention delivery and
data collection are essential for understanding trial con-
text. Important details might include the geographic lo-
cation, day and time of trial activities, space required,
and features of the inner setting (e.g. implementing
Table 2 Noteworthy changes to CONSORT 2010 items in the
CONSORT-SPI 2018 checklist
• Item 6a. The distinction between ‘primary’ versus ‘secondary’
outcomes has been removed.
• Item 11. ‘Blinding’ has been changed to ‘Awareness of assignment’
and ‘masking’ in the section heading and item wording, respectively.
These changes address concerns about the use of the term
‘blinding’ as well as the need to emphasise the issue of awareness
of assignment by providers and participants in social and
psychological intervention trials.
• Item 12. The section heading ‘Statistical methods’ has been
changed to ‘Analytical methods’ because some methods may be
qualitative in social and psychological intervention RCTs.
• Item 12a. The distinction between ‘primary’ versus ‘secondary’
outcomes has been removed.
• Item 12b. Process evaluations are specifically highlighted.
• Item 13a. The distinction between ‘primary’ versus ‘secondary’
outcomes has been removed.
• Items 13a and 16. The wording ‘number of participants’ has been
changed to ‘number’ because the term ‘participants’ is not
appropriate for RCTs in which the unit of intervention is a
geographic area. While social and psychological interventions may
target individual participants or groups of individuals such as
families or schools, they may also involve place-based techniques
that target geographic units and examine area-level effects.
However, for convenience and consistency with the CONSORT
2010 guidance [43], the CONSORT-SPI 2018 checklist and E&E will
refer to the unit targeted by the intervention as ‘participants’,
though ‘participants’ throughout this guidance is meant to stand
for ‘participating units’, or the unit being targeted by the interven-
tion [44], which may include geographic units.
• Item 15. The words ‘clinical and demographic’ have been removed
because this checklist targets interventions that may not be
medical in nature or have health outcomes, and thus to emphasise
the need to report important baseline characteristics irrespective of
their nature.
• Item 16. The parenthetical ‘(denominator)’ has been removed. The
term implied the use of dichotomous outcomes, whereas
continuous outcomes are extremely prevalent in social and
psychological intervention RCTs.
• Item 17a. The distinction between ‘primary’ versus ‘secondary’
outcomes has been removed.
• Items 23–25. The section ‘Other Information’ has been changed to
‘Important Information’ because consensus meeting participants
had concerns that ‘Other’ makes the requested information appear
to be of secondary importance to previous sections.
• Item 25. The phrase ‘such as supply of drugs’ has been removed
because drug trials are not in the purview of this extension by
definition.
• Item 26: New item. A new sub-section in ‘Important Information’
called ‘Stakeholder Involvement’ has been added because consensus
meeting participants thought such a sub-section would best fit the
three sub-items currently allocated to it
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organisation) and outer setting (e.g. external context and
environment) that might influence implementation [68].
Authors should refer to the mechanism of action when
deciding what information about setting and location to
report.
Methods: interventions
Item 5: the interventions for each group with suffi-
cient details to allow replication, including how and
when they were actually administered Complete and
transparent information about the content and delivery
of all interventions in all groups (experimental and com-
parator) [44] is vital for understanding, replicating, and
synthesising intervention effects [54, 69]. Essential infor-
mation includes: naming the interventions, what was ac-
tually delivered (e.g. materials and procedures), who
provided the interventions, how, where, when, and how
much [70]. Details about providers should include their
professional qualifications and education, expertise or
competence with the interventions or area in general,
and training and supervision for delivering the interven-
tions [71]. Tables or diagrams showing the sequence of
intervention activities, such as the participant timeline
recommended in the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) 2013
Statement [55], are often useful [72]. Authors should
avoid the sole use of labels such as ‘treatment as usual’
or ‘standard care’ because they are not uniform across
time and place [48].
CONSORT-SPI 2018 item 5a: extent to which interventions
were actually delivered by providers and taken up by
participants as planned
Frequently, interventions are not implemented as planned.
Authors should describe the actual delivery by providers
and uptake by participants of interventions for all groups,
including methods used to ensure or assess whether the
Table 3 Items to report in journal or conference abstracts for social and psychological intervention trials [13]
Section CONSORT Abstract item Relevant CONSORT-SPI item
Title Identification of the study as randomised
Authors Contact details for the corresponding author
Trial design Description of the trial design (e.g. parallel, cluster,
noninferiority)
If the unit of random assignment is not the individual, refer
to CONSORT for Cluster Randomised Trials and report the
items included in its extension for abstracts [8]
Methods
Participants Eligibility criteria for participants and the settings where
the data were collected
When applicable, eligibility criteria for the setting of
intervention delivery and the eligibility criteria for the
persons who delivered the interventions
Interventions Interventions intended for each group
Objective Specific objective or hypothesis If pre-specified, how the intervention was hypothesised
to work
Outcomes Clearly defined primary outcome for this report
Randomisation How participants were allocated to interventions
Awareness of
assignment
Who was aware of intervention assignment after
allocation (for example, participants, providers,
those assessing outcomes), and how any masking
was done
Results
Number randomly
assigned
Number randomised to each group
Recruitment Trial status
Interventions Extent to which interventions were actually delivered by
providers and taken up by participants as planned
Number analysed Number analysed in each group
Outcomes For the primary outcome, a result for each group
and the estimated effect size and its precision
Harms Important adverse events or side effects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
Funding Source of funding
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interventions were delivered by providers and taken up by
participants as intended [69]. Quantitative or qualitative
process evaluations [51] may be used to assess what pro-
viders actually did (e.g. recording and coding sessions),
the amount of an intervention that participants received
(e.g. recording the number of sessions attended), and con-
tamination across intervention groups [73, 74]. Authors
should distinguish planned systematic adaptations (e.g.
tailoring) from modifications that were not anticipated in
the trial protocol. When this information cannot be in-
cluded in a single manuscript, authors should use online
supplements, additional reports, and data repositories to
provide this information.
CONSORT-SPI 2018 item 5b: where other informational
materials about delivering the interventions can be
accessed
Authors should indicate where readers can find suffi-
cient information to replicate the interventions, such as
intervention protocols [75], training manuals [48], or
other materials (e.g. worksheets and websites) [54]. For
example, new online platforms such as the Open Science
Framework allow researchers to share some or all of
their study materials freely (https://osf.io).
CONSORT-SPI 2018 item 5c: when applicable, how
intervention providers were assigned to each group
Some trials assign specific providers to different conditions
to prevent expertise and allegiance from confounding the
results. Authors should report whether the same people
delivered the experimental and comparator interventions,
whether providers were nested within intervention groups,
and the number of participants assigned to each provider.
Methods: outcomes
Item 6a: completely define pre-specified outcomes,
including how and when they were assessed All out-
comes should be defined in sufficient detail for others to
reproduce the results using the trial data [50, 76]. An
outcome definition includes: (1) the domain (e.g. depres-
sion), (2) the measure (e.g. the Beck Depression Inven-
tory II Cognitive subscale), (3) the specific metric (e.g. a
value at a time point, a change from baseline), (4) the
Table 4 Items to report in the abstract for cluster randomised social and psychological intervention trials [8]
Section CONSORT Abstract item Relevant CONSORT Cluster extension item
Title Identification of the study as randomised Identification of study as cluster randomised
Authors Contact details for the corresponding author
Trial design Description of the trial design (e.g. parallel, cluster,
noninferiority)
Methods
Participants Eligibility criteria for participants and the settings where
the data were collected
Eligibility criteria for clusters
Interventions Interventions intended for each group
Objective Specific objective or hypothesis Whether objective or hypothesis pertains to the
cluster level, the individual participant level, or both
Outcomes Clearly defined primary outcome for this report Whether the primary outcome pertains to the cluster level,
the individual participant level, or both
Randomisation How participants were allocated to interventions How clusters were allocated to interventions
Awareness of assignment
Who was aware of intervention assignment after allocation
(for example, participants, providers, those assessing
outcomes), and how any masking was done
Results
Number randomly
assigned
Number of participants randomised to each group Number of clusters randomised to each group
Recruitment Trial status
Number analysed Number of participants analysed in each group Number of clusters analysed in each group
Outcomes For the primary outcome, a result for each group and the
estimated effect size and its precision
Results at the cluster or individual level as applicable for
each primary outcome
Harms Important adverse events or side effects
Conclusions General interpretation of the results
Trial registration Registration number and name of trial register
Funding Source of funding
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method of aggregation (e.g. mean, proportion), and (5)
the time point (e.g. 3 months post-intervention) [50]. In
addition, authors should report the methods and persons
used to collect outcome data, properties of measures or
references to previous reports with this information,
methods used to enhance measurement quality (e.g.
training of outcome assessors), and any differences in
outcome assessment between trial groups [46]. Authors
also should indicate where readers can access materials
used to measure outcomes [24]. When a trial includes a
measure (e.g. a questionnaire) that is not available pub-
licly, authors should provide a copy (e.g. through an on-
line repository or as an online supplement).
Item 6b: any changes to trial outcomes after the trial
commenced, with reasons All outcomes assessed
should be reported. If the reported outcomes differ
from those in the trial registration (Item 23) or
protocol (Item 24), authors should state which out-
comes were added and which were removed. To allow
readers to assess the risk of bias from outcome
switching, authors should also identify any changes to
level of importance (e.g. primary or secondary) [77].
Authors should provide the rationale for any changes
made and state whether these were done before or
after collecting the data.
Methods: sample size
Item 7a: how sample size was determined Authors
should indicate the intended sample size for the trial and
how it was determined, including whether the sample size
Table 5 Items to report in the main text for cluster randomised social and psychological intervention trials [8]
Section Item # Cluster extension item
Title 1a Identification as a cluster randomised trial in the title
Abstract 1b See Table 4
Introduction
Background and objectives 2a Rationale for using a cluster design
2b Whether objectives pertain to the cluster level, the individual participant level, or both
Methods
Trial design 3a Definition of cluster and description of how the design features apply to the clusters
Participants 4a Eligibility criteria for clusters
Interventions 5 Whether interventions pertain to the cluster level, the individual participant level, or both
Outcomes 6a Whether outcome measures pertain to the cluster level, the individual participant level, or both
Sample size 7a Method of calculation, number of clusters(s) (and whether equal or unequal cluster sizes are assumed),
cluster size, a coefficient of intracluster correlation (ICC or k), and an indication of its uncertainty
Randomisation
Sequence generation 8b Details of stratification or matching if used
Allocation concealment
mechanism
9 Specification that allocation was based on clusters rather than individuals and whether allocation concealment
(if any) was at the cluster level, the individual participant level, or both
Implementation 10a Who generated the random allocation sequence, who enrolled clusters, and who assigned clusters to
interventions
10b Mechanism by which individual participants were included in clusters for the trial (such as complete
enumeration, random sampling)
10c From whom consent was sought (representatives of the cluster, individual cluster members, or both) and
whether consent was sought before or after randomisation
Analytical methods 12a How clustering was taken into account
Results
Participant flow (a diagram
is strongly recommended)
13a For each group, the numbers of clusters that were randomly assigned, received the intended treatment, and
were analysed for the primary outcome
13b For each group, losses and exclusions for both clusters and individual cluster members
Baseline data 15 Baseline characteristics for the individual and cluster levels as applicable for each group
Numbers analysed 16 For each group, number of clusters included in each analysis
Outcomes and estimation 17a Results at the individual or cluster level as applicable and a coefficient of intracluster correlation (ICC or k) for
each primary outcome
Generalisability 21 Generalisability to clusters and/or individual participants (as relevant)
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was determined a priori using a sample size calculation or
due to practical constraints. If an a priori sample size cal-
culation was conducted, authors should report the effect
estimate used for the sample size calculation and why it
was chosen (e.g. the smallest effect size of interest, from a
meta-analysis of previous trials). If an a priori sample size
calculation was not performed, authors should not
present a post hoc calculation, but rather the genuine
reason for the sample size (e.g. limitations in time or
funding) and the actual power to detect an effect for
each result (Item 17).
Item 7b: when applicable, an explanation of any in-
terim analyses and stopping guidelines Multiple stat-
istical analyses can lead to false-positive results,
especially when using stopping guidelines based on
statistical significance. Any interim analyses should be
described, including which analyses were conducted
(i.e. the outcomes and methods of analysis), when
they were conducted, and why (particularly whether
they were pre-specified [78]). Authors should also de-
scribe the reasons for stopping the trial, including any
procedures used to determine whether the trial would
be stopped early (e.g. regular meetings of a data
safety monitoring board) [79].
Methods: randomisation—sequence generation
Item 8a: method used to generate the random alloca-
tion sequence In a randomised trial, participants are
assigned to groups by chance using processes designed
to be unpredictable. Authors should describe the
method used to generate the allocation sequence (e.g. a
computer-generated random number sequence), so that
readers may assess whether the process was truly ran-
dom. Authors should not use the term ‘random’ to de-
scribe sequences that are deterministic (e.g. alternation,
order of recruitment, date of birth).
Item 8b: type of randomisation; details of any restric-
tion (such as blocking and block size) Some trials re-
strict randomisation to balance groups in size or
important characteristics. Blocking restricts randomisation
by grouping participants into 'blocks' and by assigning
participants using a random sequence within each block
[46]. When blocking is used, authors should describe how
the blocks were generated, the size of the blocks, whether
and how block size varied, and if trial staff became aware
of the block size. Stratification restricts randomisation by
creating multiple random allocation sequences based on
site or characteristics thought to modify intervention ef-
fects [46]. When stratification is used, authors should re-
port why it was used and describe the variables used for
stratification, including cut-off values for categories within
each stratum. When minimisation is used, authors should
report the variables used for minimisation and include the
statistical code. When there are no restrictions on ran-
domisation, authors should state that they used ‘simple
randomisation’ [43].
Methods: randomisation—allocation concealment
mechanism
Item 9: mechanism used to implement the random
allocation sequence, describing any steps taken to
conceal the sequence until interventions were
assigned In addition to generating a truly random se-
quence (Item 8a), researchers should conceal the sequence
to prevent foreknowledge of the intervention assignment
by persons enrolling and assigning participants. Other-
wise, recruitment and allocation could be affected by
knowledge of the next assignment. Authors should report
whether and how allocation was concealed [80, 81]. When
allocation was concealed, authors should describe the
mechanism and how this mechanism was monitored to
avoid tampering or subversion (e.g. centralised or 'third--
party' assignment, automated assignment system, sequen-
tially numbered identical containers, sealed opaque
envelopes). While masking (blinding) is not always pos-
sible, allocation concealment is always possible.
Methods: randomisation—implementation
Item 10: who generated the random allocation se-
quence, who enrolled participants, and who assigned
participants to interventions In many individually ran-
domised trials, staff who generate and conceal the random
sequence are different from the staff involved in imple-
menting the sequence. This can prevent tampering or sub-
version [48]. Other procedures may be used to ensure true
randomisation in trials in which participants (e.g. groups,
places) are recruited and then randomised at the same
time. Authors should indicate who carried out each pro-
cedure (i.e. generating the random sequence, enrolling
participants, and assigning participants to interventions)
and the methods used to protect the sequence.
Methods: awareness of assignment
Item 11a: who was aware after assignment to inter-
ventions (for example, participants, providers, those
assessing outcomes), and how any masking was done
Masking (blinding) refers to withholding information
about assigned interventions post-randomisation from
those involved in the trial [46]. Masking can reduce
threats to internal validity arising from an awareness of
the intervention assignment by those who could be in-
fluenced by this knowledge. Authors should state
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whether and how (a) participants, (b) providers, (c)
data collectors, and (d) data analysts were kept un-
aware of intervention assignment. If masking was not
done (e.g. because it was not possible), authors should
describe the methods, if any, used to assess performance
and expectancy biases (e.g. masking trial hypotheses,
measuring participant expectations) [82]. Although
masking of providers and participants is often not
possible, masking outcome assessors is usually possible,
even for outcomes assessed through interviews or obser-
vations. If examined, authors should report the extent to
which outcome assessors remained masked to partici-
pants’ intervention status.
Item 11b: if relevant, description of the similarity of
interventions Particularly because masking providers
and participants is impossible in many social and psy-
chological intervention trials, authors should describe
any differences between interventions delivered to each
group that could lead to differences in the performance
and expectations of providers and participants. Import-
ant details include differences in intervention compo-
nents and acceptability, co-interventions (or adjunctive
interventions) that might be available to some groups
and not others, and contextual differences between
groups (e.g. differences in place of delivery).
Methods: analytical methods
Item 12a: statistical methods used to compare group
outcomes Complete statistical reporting allows the reader
to understand the results and to reproduce analyses [48].
For each outcome, authors should describe the methods of
analysis, including transformations and adjustment for co-
variates, and whether the methods of analysis were chosen
a priori or decided after data were collected. In the United
States, trials funded by the National Institutes of Health
must deposit a statistical analysis plan on www.Clinical
Trials.gov with their results [62, 63]. Authors with other
funding sources should ascertain whether there are similar
requirements. For cluster randomised trials, authors should
state whether the unit analysed differs from the unit of as-
signment, and if applicable, the analytical methods used to
account for differences between the unit of assignment,
level of intervention, and the unit of analysis [8, 44, 46]. Au-
thors should also note any procedures and rationale for any
transformations to the data [46]. To facilitate full reprodu-
cibility, authors should report software used to run analyses
and provide the exact statistical code [24].
Extended CONSORT-SPI item 12a: how missing data were
handled, with details of any imputation method
Missing data are common in trials of social and
psychological interventions for many reasons, such as
participant discontinuation, missed visits, and participant
failure to complete all items or measures (even for
participants who have not discontinued the trial) [46].
Authors should report the amount of missing data,
evidence regarding the reasons for missingness, and
assumptions underlying judgements about missingness
(e.g. missing at random) [83]. For each outcome, au-
thors should describe the analysis population (i.e. par-
ticipants who were eligible to be included in the
analysis) and the methods for handling missing data,
including procedures to account for missing partici-
pants (i.e. participants who withdrew from the trial,
did not complete an assessment, or otherwise did not
provide data) and procedures to account for missing
data items (i.e. questions that were not completed on
a questionnaire) [76]. Imputation methods, which aim
to estimate missing data based on other data in the
dataset, can influence trial results [84]. When imput-
ation is used, authors should describe the variables
used for imputation, the number of imputations per-
formed, the software procedures for executing the im-
putations, and the results of any sensitivity analyses
conducted to test assumptions about missing data
[84]. For example, it is often helpful to report results
without imputation to help readers evaluate the con-
sequences of imputing data.
Item 12b: methods for additional analyses, such as
subgroup analyses, adjusted analyses, and process
evaluations In addition to analysing impacts on primary
and secondary outcomes, trials often include additional
analyses, such as subgroup analyses and mediation ana-
lyses to investigate processes of change [51, 85]. All ana-
lyses should be reported at the same level of detail.
Authors should indicate which subgroup analyses were
specified a priori in the trial registration or protocol
(Items 23 and 24), how subgroups were constructed, and
distinguish confirmatory analyses from exploratory ana-
lyses. For adjusted analyses, authors should report the
statistical procedures and covariates used and the ration-
ale for these.
Additionally, qualitative analyses may be used to inves-
tigate processes of change, implementation processes,
contextual influences, and unanticipated outcomes [51].
Authors should indicate whether such analyses were
undertaken or are planned (and where they are or will
be reported if so). Authors should report methods and
results of qualitative analyses according to reporting
standards for primary qualitative research [86].
Results: participant flow
Item 13a: for each group, the numbers randomly
assigned, receiving intended treatment, and analysed
for the outcomes
Grant et al. Trials  (2018) 19:406 Page 11 of 18
CONSORT-SPI item 13a: where possible, the number
approached, screened, and eligible prior to random
assignment, with reasons for non-enrolment
Attrition after randomisation can affect internal validity
(i.e. by introducing selection bias), and attrition before
or after randomisation can affect generalisability [46].
Authors should report available information about the
total number of participants at each stage of the trial,
with reasons for non-enrolment (i.e. before randomisa-
tion) or discontinuation (i.e. after randomisation). Key
stages typically include: approaching participants,
screening for potential eligibility, assessment to confirm
eligibility, random assignment, intervention receipt, and
outcome assessment. As there may be delays between
each stage (e.g. between randomisation and initiation of
the intervention) [87], authors should include a flow dia-
gram to describe trial attrition in relation to each of
these key stages (Fig. 1; Additional file 4)
Item 13b: for each group, losses and exclusions after
randomisation, together with reasons Authors should
report participant attrition and data exclusion by the re-
search team for each randomised group at each follow-up
point [48]. Authors should distinguish between the number
of participants who deviate from the intervention protocol
but continue to receive an intervention, discontinue an
intervention but continue to provide outcome data,
discontinue the trial altogether, and were excluded by the
investigators. Authors should provide reasons for each loss
(e.g. lost contact, died) and exclusion (e.g. excluded by the
investigators because of poor adherence to intervention
protocol), and indicate the number of persons who discon-
tinued for unknown reasons.
Results: recruitment
Item 14a: dates defining the periods of recruitment
and follow-up The dates of a trial and its activities pro-
vide readers some information about the historical context
of the trial [48]. The SPIRIT 2013 Statement includes a
table that authors can use to provide a complete schedule
of trial activities, including recruitment practices,
pre-randomisation assessments, periods of intervention
delivery, a schedule of post-randomisation assessments,
and when the trial was stopped [55]. In the description,
authors should define baseline assessment and follow-up
times relative to randomisation. For example, by itself,
‘4-week follow-up’ is unclear and could mean different
things if meant after randomisation or after the end of an
intervention.
Item 14b: why the trial ended or was stopped Authors
should state why the trial was stopped. Trials might be
stopped for reasons decided a priori (e.g. sample size
reached and predetermined follow-up period completed)
or in response to the results. For trials stopped early in
response to interim analyses (Item 7b), authors should
state the reason for stopping (e.g. for safety or futility)
and whether the stopping rule was decided a priori. If
applicable, authors should describe other reasons for
stopping, such as implementation challenges (e.g. could
not recruit enough participants) or extrinsic factors (e.g.
a natural disaster). Authors should indicate whether
there are plans to continue collecting outcome data (e.g.
long-term follow-up).
Results: baseline data
Item 15: a table showing baseline characteristics for
each group
CONSORT-SPI item 15: include socioeconomic variables
where applicable
Authors should provide a table summarising all data col-
lected at baseline, with descriptive statistics for each ran-
domised group. This table should include all important
characteristics measured at baseline, including
pre-intervention data on trial outcomes, and potential
prognostic variables. Authors should pay particular at-
tention to topic-specific information related to socio-
economic and other inequalities [88–90]. For
continuous variables, authors should report the aver-
age value and its variance (e.g. mean and standard
deviation). For categorical variables, authors should
report the numerator and denominator for each cat-
egory. Authors should not use standard errors and
confidence intervals for baseline data because these
are inferential (rather than descriptive): inferential sta-
tistics assess the probability that observed differences
occurred by chance, and all baseline differences in
randomised trials occur by chance [91].
Results: numbers analysed
Item 16: for each group, number included in each
analysis and whether the analysis was by original
assigned groups While a flow diagram is helpful for in-
dicating the number of participants at each trial stage,
the number of participants included in each analysis
often differs across outcomes and analyses [44]. Authors
should report the number of participants per interven-
tion group for each analysis, so readers can interpret the
results and perform secondary analyses of the data. For
each outcome, authors should also identify the analysis
population and the method used for handling missing
data (Item 12a) [76].
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Results: outcomes and estimation
Item 17a: for each outcome, results for each group,
and the estimated effect size and its precision (such
as 95% confidence interval) For each outcome in a trial,
authors should report summary results for all analyses, in-
cluding results for each trial group and the contrast be-
tween groups, the estimated magnitude of the difference
(effect size), the precision or uncertainty of the estimate
(e.g. 95% confidence interval or CI), and the number of
people included in the analysis in each group. The p value
does not describe the precision of an effect estimate, and
authors should report precision even if the difference be-
tween groups is not statistically significant [46]. For cat-
egorical outcomes, summary results for each analysis
should include the number of participants with the event
of interest. The effect size can be expressed as the risk ra-
tio, odds ratio, or risk difference and its precision (e.g.
95% CI). For continuous outcomes, summary results for
each analysis should include the average value and its vari-
ance (e.g. mean and standard error). The effect size is usu-
ally expressed as the mean difference and its precision
(e.g. 95% CI). Summary results are often more clearly pre-
sented in a table rather than narratively in text.
CONSORT-SPI item 17a: indicate availability of trial data
As part of the growing open-science movement, triallists
are increasingly expected to maintain their datasets, linked
via trial registrations and posted in trusted online repositor-
ies (see http://www.bitss.org/resource-tag/data-repository/),
to facilitate reproducibility of reported analyses and future
secondary data analyses. Data sharing is also associated
with higher citations [92]. Authors should indicate whether
and how to obtain trial datasets, including any metadata
and analytic code needed to replicate the reported analyses
[24, 93]. Any legal or ethical restrictions on making the trial
data available should be described [93].
Item 17b: for binary outcomes, presentation of both
absolute and relative effect sizes is recommended By
themselves, neither relative measures nor absolute mea-
sures provide comprehensive information about inter-
vention effects. Authors should report relative effect
sizes (e.g. risk ratios) to express the strength of effects
and absolute effect sizes (e.g. risk differences) to indicate
actual differences in events between interventions [94].
Results: ancillary analyses
Item 18: results of any other analyses performed, in-
cluding subgroup analyses, adjusted analyses, and
process evaluations, distinguishing pre-specified
from exploratory Authors should report the results for
each additional analysis described in the methods (Item
12b), indicating the number of analyses performed for
each outcome, which analyses were pre-specified, and
which analyses were not pre-specified. When evaluating
effects for subgroups, authors should report interaction
effects or other appropriate tests for heterogeneity be-
tween groups, including the estimated difference in the
intervention effect between each subgroup with confi-
dence intervals. Comparing tests for the significance of
change within subgroups is not an appropriate basis for
evaluating differences between subgroups. If reporting
adjusted analyses, authors should provide unadjusted re-
sults as well. Authors reporting any results from qualita-
tive data analyses should follow reporting standards for
qualitative research [86], though adequately reporting
these findings will likely require more than one journal
article [51].
Results: harms
Item 19: all important harms or unintended effects
in each group (for specific guidance, see CONSORT
for Harms) [14] Social and psychological interventions
have the potential to produce unintended effects, both
harmful and beneficial [95]. These may be identified in the
protocol and relate to the theory of how the interventions
are hypothesised to work (Item 2b) [56], or they may be
unexpected events that were not pre-specified for assess-
ment. Harms may include indirect effects such as
increased inequalities at the level of groups or places that
result from the intervention [89]. When reporting quanti-
tative data on unintended effects, authors should indicate
how they were defined and measured, and the frequency
of each event per trial group. Authors should report all re-
sults from qualitative investigations that identify possible
unintended effects because this information may help
readers make informed decisions about using interven-
tions in future research and practice.
Discussion: limitations
Item 20: trial limitations, addressing sources of po-
tential bias, imprecision, and, if relevant, multiplicity
of analyses Authors should provide a balanced discus-
sion of the strengths and limitations of the trial and
its results. Authors should consider issues related to
risks of bias, precision of effect estimates, the use of
multiple outcomes and analyses, and whether the
intervention was delivered and taken up as planned.
Discussion: generalisability
Item 21: generalisability (external validity, applicabil-
ity) of the trial findings Authors should address gen-
eralisability, or the extent to which the authors
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believe that trial results can be expected in other situ-
ations [66]. Authors should explain how statements
about generalisability relate to the trial design and
execution. Key factors to consider discussing include:
recruitment practices, eligibility criteria, sample character-
istics, facilitators and barriers to intervention implementa-
tion, the choice of comparator, what outcomes were
assessed and how, length of follow-up, and setting charac-
teristics [46, 66].
Discussion: interpretation
Item 22: interpretation consistent with results, balan-
cing benefits and harms, and considering other rele-
vant evidence Authors should provide a brief
interpretation of findings in light of the trial’s objectives
or hypotheses [46]. Authors may wish to discuss plaus-
ible alternative explanations for results other than dif-
ferences in effects between interventions [44]. Authors
should contextualise results and identify the additional
knowledge gained by discussing how the trial adds to
the results of other relevant literature [96], including
references to previous trials and systematic reviews. If
theory was used to inform intervention development or
evaluation (Item 2b), authors should discuss how the
results of the trial compare with previous theories
about how the interventions would work [97, 98]. Au-
thors should consider describing the practical
significance of findings; the potential implications of
findings to theory, practice and policy; and specific
areas of future research to address gaps in current
knowledge [49]. Authors should avoid distorted
presentation or 'spin' when discussing trial findings [99,
100].
Important information: registration
Item 23: registration number and name of trial regis-
try Trial registration is the posting of a minimum infor-
mation set in a public database, including: eligibility
criteria, all outcomes, intervention protocols, and
planned analyses [101]. Trial registration aids systematic
reviews and meta-analyses, and responds to
decades-long calls to prevent reporting biases [102–104].
Trial registration is now required for all trials published
by journals that endorse the International Committee of
Medical Journal Editors guidelines and for all trials
funded by the National Institutes of Health in the United
States as well as the Medical Research Council and
National Institute for Health Research in the UK
[62, 63, 105, 106].
Trials should be registered prospectively, before begin-
ning enrolment, normally in a publicly accessible website
managed by a registry conforming to established standards
[101, 105]. Authors should report the name of the trial
registry, the unique identification number for the trial pro-
vided by that registry, and the stage at which the trial was
registered. If authors did not register their trial, they
should report this and the reason for not registering.
Registries used in clinical medicine (e.g. www.Clinical-
Trials.gov) are suitable for social and psychological inter-
vention trials with health outcomes [107, 108], and several
registries exist specifically for social and psychological in-
terventions (http://www.bitss.org/resource-tag/registry/).
Important information: protocol
Item 24: where the full trial protocol can be accessed,
if available Details about trial design should be described
in a publicly accessible protocol (e.g. published manuscript,
report in a repository) that includes a record of all amend-
ments made after the trial began. Authors should report
where the trial protocol can be accessed. Guidance on
developing and reporting protocols has recently been pub-
lished [55]. Authors of social and psychological intervention
trials who face difficulty finding a journal that publishes
trial protocols could search for journals supporting the Reg-
istered Reports format (https://cos.io/rr/) or upload their
trial protocols to relevant preprint servers such as PsyArXiv
(https://psyarxiv.com/) and SocArXiv (https://osf.io/pre
prints/socarxiv).
Important information: funding
Item 25a: sources of funding and other support, role
of funders Information about trial funding and support is
important in helping readers to identify potential conflicts
of interest. Authors should identify and describe all sources
of monetary or material support for the trial, including sal-
ary support for trial investigators and resources provided
or donated for any phase of the trial (e.g. space, interven-
tion materials, assessment tools). Authors should report
the name of the persons or entities supported, the
name of the funder, and the award number. They
should also specifically state if these sources had any
role in the design, conduct, analysis, and reporting of
the trial, and the nature of any involvement or influ-
ence. If funders had no involvement or influence, au-
thors should specifically report this.
CONSORT-SPI item 25b: declaration of any other potential
interests
In addition to financial interests, it is important that au-
thors declare any other potential interests that may be
perceived to influence the design, conduct, analysis, or
reporting of the trial following established criteria [109].
Examples include allegiance to or professional training in
evaluated interventions. Authors should err on the side of
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caution in declaring potential interests. If authors do not
have any financial, professional, personal, or other poten-
tial interests to declare, they should declare this explicitly.
Important information: stakeholder involvement
CONSORT-SPI new item – Item 26a: any involvement of the
intervention developer in the design, conduct, analysis, or
reporting of the trial
Intervention developers are often authors of trial
reports. Because involvement of intervention developers
in trials may be associated with effect sizes [110, 111],
authors should report whether intervention developers
were involved in designing the trial, delivering the inter-
vention, assessing the outcomes, or interpreting the data.
Authors should also disclose close collaborations with
the intervention developers (e.g. being a former student
of the developer, serving on an advisory or consultancy
board related to the intervention), and any legal or intel-
lectual rights related to the interventions, especially if
these could lead to future financial interests.
CONSORT-SPI new item – Item 26b: other stakeholder
involvement in trial design, conduct, or analyses
Researchers are increasingly called to consult or collab-
orate with those who have a direct interest in the results
of trials, such as providers, clients, and payers [112].
Stakeholders may be involved in designing trials (e.g.
choosing outcomes) [76], delivering interventions, or
interpreting trial results. Stakeholder involvement may
help to better ensure the acceptability, implementability,
and sustainability of interventions as they move from
research to real-world settings [113]. When applicable,
authors should describe which stakeholders were
involved, how they were recruited, and how they were
involved in various stages of the trial [114]. Authors may
find reporting standards on public involvement in
research useful [115].
CONSORT-SPI new item – Item 26c: incentives offered as
part of the trial
Incentives offered to participants, providers, organisations,
and others involved in a trial can influence recruitment, en-
gagement with the interventions, and quality of interven-
tion delivery [116]. Incentives include monetary
compensation, gifts (e.g. meals, transportation, access to
services), academic credit, and coercion (e.g. prison diver-
sion) [48]. When incentives are used, authors should make
clear at what trial stage and for what purpose incentives are
offered, and what these incentives entail. Authors also
should state whether incentives differ by trial group, such
as compensation for participants receiving the experimental
rather than the comparator interventions.
Conclusions
The results of RCTs are of optimal use when authors re-
port their methods and results accurately, completely,
and transparently. The CONSORT-SPI 2018 checklist
can help researchers to design and report future trials,
and provide guidance to peer reviewers and editors for
evaluating manuscripts, to funders in setting reporting
criteria for grant applications, and to educators in teach-
ing trial methods. Each item should be addressed before
or within the main trial paper (e.g. in the text, as an on-
line supplement, or by reference to a previous report).
The level of detail required for some checklist items will
depend on the nature of the intervention being evalu-
ated [70], the trial phase [117], and whether the trial in-
volves an evaluation of process or implementation [74].
CONSORT-SPI 2018, like all CONSORT guidance,
is an evolving document with a continuous and itera-
tive process of assessment and refinement over time.
The authors welcome feedback about the checklist
and this E&E document, particularly as new evidence
in this area and greater experience with this guidance
develop. For instance, interested readers can provide
feedback on whether some of the new items in
CONSORT-SPI 2018 that are applicable to other
types of trials (e.g. handling missing data and avail-
ability of trial data) should be incorporated into the
next update of the main CONSORT Statement. We
also encourage journals in the behavioural and social
sciences to join the hundreds of medical journals that
endorse CONSORT guidelines, and to inform us of
such endorsement. The ultimate benefit of this col-
lective effort should be better practices leading to bet-
ter health and quality of life.
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